Muutke küpsiste eelistusi

E-raamat: Hot topics in Cardio-Oncology

Edited by (Federico II University, Italy), Edited by (University of Turin, Italy), Edited by (Federico II University, Italy), Edited by (University of Turin, Italy)
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 44,71 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Over the last years, thanks to growing advances in the field of cancer therapies, a considerable decrease in cancer mortality has been observed. Unfortunately, such therapies have shown a wide spectrum of cardiotoxicities.

This book provides the readers with the latest advances and insights in the ever-expanding field of Cardio-Oncology. Specific topics discussed in the book include the potential role of inflammation in Cardio-Oncology and the description of the different manifestations of cardiotoxicities (including vascular toxicity, systemic hypertension, arrhythmias), analyzing the complex relationships between cancer and heart failure, two conditions whose prevalence increases with ageing. Furthermore, the role of biomarkers and imaging in cardio-oncology is discussed.
List of Figures
ix
List of Tables
xi
List of Contributors
xiii
List of Abbreviations
xvii
Introduction xxi
Valentina Mercurio
Pasquale Pagliaro
Claudia Penna
Carlo G. Tocchetti
1 Inflammation in Cardio-Oncology
1(20)
Remo Poto
Giancarlo Marone
Flora Pirozzi
Alessandra Cuomo
Antonio Cararmante
Maria Rosaria Galdiero
Carlo G. Tocchetti
Valentina Mercurio
Gilda Varricchi
1.1 Introduction
2(1)
1.2 Inflammation in Cardiac Injury and Repair
2(2)
1.3 Immune Checkpoint Inhibitors
4(4)
1.4 CAR-T Cell Therapy
8(1)
1.5 Inflammation at the Crossroad Between Cancer and Cardiovascular Diseases
9(3)
References
12(9)
2 Vascular Toxicity and Thromboembolic Risk in Cardio-Oncology
21(20)
Daniela Di Lisi
Giuseppina Novo
2.1 Introduction
21(1)
2.2 Acute Coronary Syndrome (ACS) and Coronary Artery Diseases (CAD)
22(3)
2.3 Other Drugs that Cause Myocardial Infarction and Coronary Artery Diseases
25(2)
2.4 Arterial Hypertension
27(1)
2.5 Peripheral Artery Occlusive Diseases
28(1)
2.6 Pulmonary Hypertension
29(1)
2.7 Stroke
29(1)
2.8 Thromboembolic Risk and Atrial Fibrillation
30(1)
2.9 Prevention and Treatment of Vascular Toxicity
31(1)
References
32(9)
3 Hypertensive Oncologic Patients
41(10)
Giacomo Tini
Massimo Volpe
Paolo Spallarossa
3.1 Introduction
41(1)
3.2 Implications of Arterial Hypertension in Patients Undergoing Anticancer Treatments
42(2)
3.2.1 Anthracyclines
42(1)
3.2.2 Carfilzomib
42(1)
3.2.3 Anti-vascular endothelial growth factor agents
43(1)
3.3 Management of Arterial Hypertension in Oncologic Patients
44(3)
References
47(4)
4 Cardiac Surgery and Percutaneous Coronary Intervention in Patients With Cancer
51(12)
Fabrizio D'Ascenzo
Stefano Salizzoni
Ovidio De Filippo
Guglielmo Gallone
Francesco Bruno
Mauro Rinaldi
Gaetano Maria De Ferrari
4.1 Introduction
51(7)
4.1.1 The complex interplay between ACS and cancer: bench and pharmacological data
51(1)
4.1.2 The complex interplay between ACS and cancer: the role of the disease
52(1)
4.1.3 The complex interplay between ACS and cancer: the role of chemotherapy and of radiotherapy
53(2)
4.1.4 The complex interplay between ACS and cancer: clinical data
55(2)
4.1.5 The complex interplay between cardiac surgery and cancer: clinical data
57(1)
References
58(5)
5 Cancer Therapy-Induced Arrhythmias
63(20)
Davide Castagno
Vincenzo Cusenza
Gaetano Maria De Ferrari
5.1 Introduction
63(15)
5.1.1 Epidemiology
63(1)
5.1.2 Etiology and Pathogenesis
64(3)
5.1.3 Diagnosis, Physical Examination, and Diagnostic Tests
67(2)
5.1.4 Clinical Characteristics
69(1)
5.1.5 Treatment
69(7)
5.1.6 Prophylaxis
76(2)
References
78(5)
6 Cancer in the Heart Failure Population
83(24)
Alessandra Cuomo
Flora Pirozzi
Francesco Paudice
Giovanni Perrotta
Giovanni D'Angelo
Antonio Carannante
Carlo Gabriele Tocchetti
Valentina Mercurio
Pietro Ameri
6.1 Introduction
84(1)
6.2 Heart Failure and New Onset Cancer: Epidemiology
84(3)
6.3 Mechanisms of Cancer Development in the Heart Failure Population
87(4)
6.4 Cancer in Heart Failure Patients: Clinical Implications
91(5)
6.5 Conclusions
96(1)
References
97(10)
7 Metabolomics in the Identification of New Biomarkers in Cardio-Oncology
107(14)
Christian Cadeddu Dessalvi
Martino Deidda
Antonio Noto
Giuseppe Mercuro
7.1 Introduction
107(1)
7.2 Metabolomics
108(2)
7.3 Metabolomics in Cardio-Oncology
110(4)
7.4 Metabolomics Profiling Cardioprotective Strategies
114(1)
7.5 Conclusion
115(1)
References
116(5)
8 Imaging in Cardio-Oncology
121(26)
Roberta Manganaro
Concetta Zito
8.1 Introduction
121(1)
8.2 Conventional Echocardiography
122(5)
8.2.1 LV systolic and diastolic function
122(2)
8.2.2 RV function
124(1)
8.2.3 Valvular heart disease
125(1)
8.2.4 Pericardial disease
126(1)
8.3 Advanced Echocardiography
127(2)
8.3.1 Myocardial deformation imaging
127(2)
8.4 Three-Dimensional Echocardiography (3DE)
129(1)
8.5 Assessment of Cardiotoxicity Risk and Echocardiography Surveillance According to Anticancer Treatment
129(4)
8.6 Other imaging modalities
133(2)
8.6.1 Cardiac Magnetic Resonance
133(2)
8.7 Cardiac Nuclear Imaging
135(1)
8.8 Multimodality Imaging in Screening and Follow-up in Radiotherapy
136(2)
8.8.1 Pericardial disease
136(1)
8.8.2 Myocardial dysfunction
136(1)
8.8.3 Valvular heart disease (see also above)
137(1)
8.8.4 Coronary artery disease
137(1)
8.9 Conclusions and Future Directions
138(1)
References
139(8)
9 Venous Thromboembolism in Cardio-Oncology
147(18)
Ciro Santoro
Mario Enrico Canonico
9.1 Introduction
147(1)
9.2 Biological Mechanism of Cancer-Related Thrombosis
148(1)
9.3 Epidemiology and Risk Stratification
148(3)
9.4 Clinical Presentation
151(2)
9.5 Recurrent Venous Thrombosis and Treatment in Cancer Population
153(2)
9.6 Prognosis
155(1)
9.7 Thromboprophylaxis
155(1)
9.8 Conclusions
156(1)
References
157(6)
Conclusions and Remarks
163(1)
Valentino Mercurio
Pasquale Pagliaro
Claudia Penna
Carlo G. Tocchetti
References
164(1)
Index 165(2)
About the Editors 167
Dr Valentina Mercurio got her MD in 2010, her Board in Internal Medicine in 2016 and her PhD in 2019 at Federico II University, Naples, Italy. She is currently Assistant Professor of Medicine in the Department of Translational Medical Sciences, Federico II University, Naples, Italy, since 2019, where she coordinates the Echocardiographic Laboratory of the Cardio-Oncology Unit and of the Heart Failure outpatient unit mostly dedicated to post ischemic heart failure, right ventricular dysfunction and pulmonary hypertension, and in particular to the follow-up of oncologic patient before, during and after undergoing antineoplastic therapies. Her previous studies and ongoing collaborations with Prof. Paul Hassoun and Prof. Monica Mukherjee at Johns Hopkins University, Baltimore, MD; USA are mostly focused on pulmonary hypertension and right ventricular dysfunction, and she has established herself as a Pulmonary Hypertension basic and clinical investigator in Naples. Since 2019, Dr Mercurio is Fellow of the Italian Society of Cardiology and nucleus member of the working group on drug-induced cardiotoxicity and cardio-protection, and a member of the ESC Council of Cardio-Oncology, member of the Heart Failure Association, and of the WG Myocardial Function and of the WG on Pulmonary Circulation & Right Ventricular Function of the ESC, and of the PVRI (Pulmonary Vascular Research Institute).



Prof Pasquale Pagliaro, M.D., Ph.D was born in Rossano, Italy, in 1961. He is a full professor of Physiology at University of Turin (Italy) Department of Clinical and Biological Sciences. He is also member of the National Institute for Cardiovascular Researches (Bologna, Italy).



Degrees awarded: MD, University of Turin (Italy), Thesis topic: Coronary Pathophysiology, 1988. PhD, University of Turin (Italy), Thesis topic: Endothelial Physiology, 1994. Research Fellowship in Medicine-Cardiovascular at the Johns Hopkins University Baltimore (USA); Research topic: Coronary and Endothelial Physiology, 1997-99. Research experience/other activities: Prof Pagliaro is PI in a lab studying coronary physiology and pathophysiology, and cardioprotection. His recent research concerns endothelial factors and other endogenous substances in triggering protective signaling pathways. Prof Pagliaros lab also focusses on redox-signaling and mitochondrial function.



Prof Pagliaro served as an Ordinary member of Italian Society of Physiology, The Physiological Society (London), Italian Society of Cardiology, European Society of Cardiology, Italian Society of Cardiovascular Research (SIRC). He served as Vice-coordinator of the nucleus and as member of the working group on drug-induced cardiotoxicity and cardio-protection of the Italian Society of Cardiology. Prof Pagliaro is Past-President of SIRC and the Coordinator of the PhD in Experimental Medicine and Therapy of the University of Turin.



Prof Claudia Penna, BSc.D., Ph.D was born in Asti, Italy, in 1967. She is an associate professor of Physiology at University of Turin (Italy) Department of Clinical and Biological Sciences. She is also member of the National Institute for Cardiovascular Research (Bologna, Italy).



Degrees awarded: BSc, University of Turin (Italy), Thesis topic: Effect of venom in the isolated heart, 1991. Specialist of Clinical Pathology, University of Turin (Italy), thesis topic: Modulation of cardiac current by Nitric Oxide, 1995, PhD, University of Turin (Italy), thesis topic: Hyperaemic response and Ischemic Preconditioning, 2000.



Research experience/other activities: cardioprotection and cardiotoxicity.



She is member of Italian Society of Physiology, the Italian Society of Cardiology and European Society of Cardiology. She served as Vice-coordinator of the nucleus and as member of the working group on drug-induced cardiotoxicity and cardio-protection of the Italian Society of Cardiology.



Prof. Carlo Gabriele Tocchetti got his MD in 1997, his Board in Cardiology in 2001 and his PhD in 2007 at Federico II University, Naples, Italy, and is currently Associate Professor of Medicine and Director of the Cardio-Oncology Unit in the Department of Translational Medical Sciences, Federico II University, Naples, Italy since 2014. He coordinates the Heart Failure outpatient unit mostly dedicated to post ischemic HF, RV dysfunction and Pulmonary Hypertension, and the follow-up of oncologic patient before, during and after undergoing antineoplastic protocols, and has established himself as a HF basic and clinical investigator. Prof. Tocchetti is Fellow of the Heart Failure Association (HFA), 2020-2022 Chair of the Study Group on Cardio-Oncology of the HFA, of the HFA Translational Research Committee, and of the WG on Myocardial Function of the European Society of Cardiology (ESC), and 2020-2022 Board Member of the ESC Council on Basic Cardiovascular Science (CBCS) and Council of Cardio-Oncology (CCO). His previous studies and ongoing collaborations with Drs Kass and Paolocci at Johns Hopkins University, Baltimore, MD, USA, have helped dissecting the cardiac contractile effects of HNO and the development of a novel HNO donor for treating human heart failure currently used in clinical trials. Hence, the main goal of his lab is to explore pathophysiologic mechanisms and therapeutic targets in cardiac dysfunction, with a particular interest on post-ischemic HF, genetic and inflammatory cardiomyopathies, Pulmonary Hypertension and RV dysfunction, and HF due to antineoplastic therapies, including novel anticancer immunotherapies and biologic drugs employed in inflammatory diseases.